Retatrutide Beats Semaglutide in Diabetes Trial

Company Eli Lilly Event Type Phase 3 topline (TRANSCEND-T2D-2) Modality Once-weekly GIP/GLP-1/glucagon triple agonist Asset Retatrutide Target GIP, GLP-1 and glucagon receptors Disease Area Type 2 diabetes Summary Lilly disclosed 80-week Phase III TRANSCEND-T2D-2 topline results on 28 October: retatrutide improved A1C and weight more…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline
US Cooperative Group Will Test Ivonescimab in Biliary Cancer